Knowledge of the details of these complex regulatory mechanisms can help to understand why combinatorial therapies, which employ DFMO to inhibit ODC, and GC7 to inhibit eIF5A hypusination, are particularly effective in the treatments of certain cancers [62]. The gene discussed is EIF5A; the disease is cancer.